Trial Profile
Phase II Study of Pemetrexed Plus Cisplatin in the Treatment of Patients With Extensive Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 08 Apr 2022 This trial has been completed (End Date: 1 Apr 2008), according to European Clinical Trials Database record.
- 02 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 02 Oct 2008 Status changed from discontinued to completed, as reported by ClinicalTrials.gov.